A detailed history of Norris Perne & French LLP transactions in Abb Vie Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 2,687 shares of ABBV stock, worth $522,030. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,687
Previous 2,663 0.9%
Holding current value
$522,030
Previous $484,000 4.96%
% of portfolio
0.04%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$154.79 - $180.76 $3,714 - $4,338
24 Added 0.9%
2,687 $460,000
Q1 2024

Apr 16, 2024

SELL
$159.82 - $182.1 $37,717 - $42,975
-236 Reduced 8.14%
2,663 $484,000
Q4 2023

Jan 22, 2024

BUY
$137.6 - $154.97 $15,548 - $17,511
113 Added 4.06%
2,899 $449,000
Q3 2023

Oct 18, 2023

BUY
$133.59 - $154.65 $53,436 - $61,860
400 Added 16.76%
2,786 $415,000
Q2 2023

Jul 19, 2023

BUY
$132.51 - $164.9 $15,901 - $19,788
120 Added 5.3%
2,386 $321,000
Q1 2023

Apr 20, 2023

BUY
$144.61 - $166.54 $26,174 - $30,143
181 Added 8.68%
2,266 $361,000
Q4 2022

Jan 24, 2023

SELL
$138.31 - $165.87 $40,386 - $48,434
-292 Reduced 12.28%
2,085 $0
Q3 2022

Oct 13, 2022

SELL
$134.21 - $153.93 $10,065 - $11,544
-75 Reduced 3.06%
2,377 $319,000
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $13,486 - $17,146
-98 Reduced 3.84%
2,452 $376,000
Q1 2022

Apr 26, 2022

SELL
$131.98 - $163.75 $158,376 - $196,500
-1,200 Reduced 32.0%
2,550 $413,000
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $20,841 - $26,370
-194 Reduced 4.92%
3,750 $508,000
Q3 2021

Oct 26, 2021

SELL
$106.4 - $120.78 $5,320 - $6,039
-50 Reduced 1.25%
3,944 $425,000
Q2 2021

Jul 20, 2021

SELL
$105.21 - $117.21 $10,521 - $11,721
-100 Reduced 2.44%
3,994 $450,000
Q1 2021

Apr 30, 2021

SELL
$102.3 - $112.62 $2.51 Million - $2.76 Million
-24,500 Reduced 85.68%
4,094 $443,000
Q4 2020

Jan 27, 2021

SELL
$80.49 - $108.67 $24,147 - $32,601
-300 Reduced 1.04%
28,594 $3.06 Million
Q3 2020

Oct 26, 2020

SELL
$85.91 - $100.83 $43,126 - $50,616
-502 Reduced 1.71%
28,894 $2.53 Million
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $220,036 - $294,441
2,999 Added 11.36%
29,396 $2.89 Million
Q1 2020

Apr 16, 2020

SELL
$64.5 - $97.79 $11,287 - $17,113
-175 Reduced 0.66%
26,397 $2.01 Million
Q4 2019

Jan 22, 2020

SELL
$72.13 - $90.25 $77,756 - $97,289
-1,078 Reduced 3.9%
26,572 $2.35 Million
Q3 2019

Oct 24, 2019

SELL
$62.98 - $75.72 $6,298 - $7,572
-100 Reduced 0.36%
27,650 $2.09 Million
Q2 2019

Jul 19, 2019

BUY
$65.7 - $83.98 $21,352 - $27,293
325 Added 1.19%
27,750 $2.02 Million
Q1 2019

Apr 29, 2019

SELL
$77.14 - $90.79 $57,855 - $68,092
-750 Reduced 2.66%
27,425 $2.21 Million
Q4 2018

Jan 28, 2019

SELL
$77.85 - $96.01 $22,887 - $28,226
-294 Reduced 1.03%
28,175 $2.6 Million
Q3 2018

Oct 29, 2018

SELL
$88.91 - $98.84 $109,092 - $121,276
-1,227 Reduced 4.13%
28,469 $2.69 Million
Q2 2018

Jul 24, 2018

BUY
$89.78 - $106.23 $14,813 - $17,527
165 Added 0.56%
29,696 $2.75 Million
Q1 2018

Apr 17, 2018

SELL
$92.01 - $123.21 $11,501 - $15,401
-125 Reduced 0.42%
29,531 $2.8 Million
Q4 2017

Jan 23, 2018

SELL
$89.56 - $98.21 $4,478 - $4,910
-50 Reduced 0.17%
29,656 $2.87 Million
Q3 2017

Nov 01, 2017

BUY
$69.85 - $89.22 $2.07 Million - $2.65 Million
29,706
29,706 $2.64 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Norris Perne & French LLP Portfolio

Follow Norris Perne & French LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.